- Latest news▼
-
23:22, September 7 How Can a Fly’s Brain Help Us Understand Human Behavior?
-
21:18, September 7 How the Pursuit of Perfect Sleep Can Keep You Awake
-
08:37, September 7 Weight-Loss Drug May Affect Aging: Scientists Discover an Unexpected Effect of Semaglutide
-
20:53, September 5 npj Science of Food: A Spoonful of Vegetable Oil Before a Carb-Rich Meal May Blunt Blood Sugar Spikes
-
13:26, September 5 In the U.S., Prescriptions for Obesity Drugs for Children Under 12 Increased 310-Fold in Seven Years
-
23:20, September 4 TCTV: New Drug Doubles Survival in Lung Cancer
-
11:10, September 4 SB: The Rule of Drinking Eight Glasses of Water a Day Has No Scientific Basis
-
08:46, September 4 JID: Popular Weight-Loss Drugs May Increase the Risk of Male Pattern Hair Loss by 7%
-
22:46, September 3 At-Home Urine Test Could Detect Most Bladder Cancer Cases, Study Finds
-
20:38, September 3 Alcohol-Related Cancer Deaths Double in the U.S. as the Number of Such Deaths Rises Over 33 Years
-
18:29, September 3 An Unexpected Paradox: Both Very Low and Very High Testosterone Levels May Be Equally Dangerous for the Heart
-
16:11, September 3 The Independent: Aging Is the Main Risk Factor for Cancer
-
14:13, September 3 CC: Age-Related Changes in Memory May Begin as Early as 50
-
08:34, September 3 Scientists Find Who May Benefit More from Coffee in Terms of Parkinson’s Disease Risk
-
23:37, September 2 LDE: Popular Diabetes Drugs Linked to Risk of a Dangerous Complication in Certain Patients
All materials
TCTV: New Drug Doubles Survival in Lung Cancer
Biotechnology companies Akeso and Summit Therapeutics reported that their new drug, ivonescimab, significantly extends the lives of patients with non-small cell lung cancer (NSCLC). In a Phase 3 clinical trial, the drug outperformed pembrolizumab, a widely used treatment that had remained the gold standard for nearly 10 years. The Clinical Trial Vanguard reports.
The HARMONi-2 study, a randomized Phase 3 clinical trial of the drug, showed that the new therapy simultaneously blocks PD-1, a protein that helps tumors evade the immune system, and VEGF, a protein that promotes the growth of blood vessels that supply tumors. Previously, scientists had been concerned about using such blocking combinations because of the risk of fatal bleeding in patients with squamous cell carcinoma. However, the innovative molecule proved to be sufficiently safe that China has already lifted these restrictions, expanding the pool of potential patients for further trials.
The drug had already demonstrated a significant advantage in delaying disease progression: 11.14 months compared with 5.82 months with the comparator. Now, it has also demonstrated an advantage in overall survival, a measure that can directly influence clinical treatment guidelines. Exact figures have not yet been disclosed, and researchers plan to present them at an upcoming international conference.
Pembrolizumab had remained the standard first-line treatment for NSCLC for nearly a decade in patients whose tumors express the relevant biomarker. The earlier drug targeted only PD-1 on the surface of immune cells (T lymphocytes), effectively releasing an immune “brake” and allowing the body to recognize and destroy cancer cells.
In 2022, U.S. company Summit Therapeutics acquired the rights to develop and commercialize ivonescimab in the United States and Europe for $500 million. The U.S. Food and Drug Administration (FDA) is currently reviewing the application for approval of the new drug, with a final decision expected as early as November.
Follow NEWS.am Medicine on Facebook and Twitter
- Most read
month
week
day
- An Unexpected Paradox: Both Very Low and Very High Testosterone Levels May Be Equally Dangerous for the Heart 950
- Alcohol-Related Cancer Deaths Double in the U.S. as the Number of Such Deaths Rises Over 33 Years 872
- The Independent: Aging Is the Main Risk Factor for Cancer 852
- CC: Age-Related Changes in Memory May Begin as Early as 50 847
- LDE: Popular Diabetes Drugs Linked to Risk of a Dangerous Complication in Certain Patients 845
- At-Home Urine Test Could Detect Most Bladder Cancer Cases, Study Finds 832
- Scientists Find Who May Benefit More from Coffee in Terms of Parkinson’s Disease Risk 715
- SB: The Rule of Drinking Eight Glasses of Water a Day Has No Scientific Basis 52
- TCTV: New Drug Doubles Survival in Lung Cancer 49
- Weight-Loss Drug May Affect Aging: Scientists Discover an Unexpected Effect of Semaglutide 48
- JID: Popular Weight-Loss Drugs May Increase the Risk of Male Pattern Hair Loss by 7% 47
- npj Science of Food: A Spoonful of Vegetable Oil Before a Carb-Rich Meal May Blunt Blood Sugar Spikes 46
- In the U.S., Prescriptions for Obesity Drugs for Children Under 12 Increased 310-Fold in Seven Years 42
- How the Pursuit of Perfect Sleep Can Keep You Awake 42
- How Can a Fly’s Brain Help Us Understand Human Behavior? 38
- Find us on Facebook
- Poll